Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer

Meng, Y., Yu, B., Huang, H., Peng, Y., Li, E., Yao, Y., Song, C., Yu, W., Zhu, K., Wang, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02005 · Cited by 76

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

Chen, H., Lai, M., Zhang, T., Chen, Y., Tong, L., Zhu, S., Zhou, Y., Ren, X., Ding, J., Xie, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00168 · Cited by 76

Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)

Șandor, A., Ionuţ, I. A., Marc, G., Oniga, I., Eniu, D. T., & Oniga, O. (2023) · Pharmaceuticals · doi:10.3390/ph16040534 · Cited by 79

Activating ERBB4 mutations in non-small cell lung cancer

Kurppa, K. J., Denessiouk, K. A., Johnson, M. S., & Elenius, K. (2015) · Oncogene · doi:10.1038/onc.2015.185 · Cited by 76

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance

Hegedüs, C., Truta-Feles, K., Antalffy, G., Várady, G., Német, K., Özvegy‐Laczka, C., Kéri, G., Őrfi, L., Szakács, G., Settleman, J. E., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.04.010 · Cited by 76

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

Tam, I. Y. S., Leung, E. L., Tin, V. P., Chua, D. T.-T., Sihoe, A. D., Cheng, L., Chung, L.-P., & Wong, M. P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1219 · Cited by 76

FOXM1 Promotes Lung Adenocarcinoma Invasion and Metastasis by Upregulating SNAIL

Wei, P., Zhang, N., Wang, Y., Li, D., Wang, L., Sun, X., Shen, C., Yang, Y., Zhou, X., & Du, X. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10634 · Cited by 76

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Zuo, W., Jiang, Y., Wang, Y.-J., Xu, X., Hu, X. Y., Liu, G., Wu, J., Di, G., Yu, K., & Shao, Z.-M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3036 · Cited by 76

Are liquid biopsies a surrogate for tissue EGFR testing?

Goldman, J. W., Noor, Z. S., Remón, J., Besse, B., & Rosenfeld, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx706 · Cited by 77

Cytology Smears in the Era of Molecular Biomarkers in Non–Small Cell Lung Cancer: Doing More With Less

Lozano, M. D., Echeveste, J. I., Abengozar‐Muela, M., Mejías, L. D., Idoate, M. A., Calvo, A., & de Andrea, C. E. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0208-ra · Cited by 76

Polymer nanostructures for bioapplications induced by laser treatment

Slepička, P., Siegel, J., Lyutakov, O., Kasálková, N. S., Kolská, Z., Bačáková, L., & Švorčı́k, V. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.12.011 · Cited by 75

Cancer Cytosensing Approaches in Miniaturized Settings Based on Advanced Nanomaterials and Biosensors

Purohit, B., Kumar, A., Mahato, K., Roy, S., & Chandra, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818823-1.00009-0 · Cited by 75

Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness

Yan, R., Fan, X., Xiao, Z., Liu, H., Huang, X., Liu, J., Zhang, S., Yao, J., An, G., & Ge, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.030 · Cited by 75

EGFR T790M resistance mutation in non small-cell lung carcinoma

Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 76

Carbohydrate to carbohydrate interaction in development process and cancer progression

Handa, K., & Hakomori, S. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9380-7 · Cited by 75

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

Kim, H. J., Lee, K. Y., Kim, Y., Kim, K. S., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., Lee, J. C., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.08.005 · Cited by 75

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Wang, Z., & Fang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s69690 · Cited by 80

Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer

Ju, L., Zhou, C., Li, W., & Yan, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22888 · Cited by 75

A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases

Monaco, S. E., Nikiforova, M. N., Cieply, K. M., Teot, L. A., Khalbuss, W. E., & Đačić, S. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.06.019 · Cited by 75

Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth

Ahmed, A. U., Schmidt, R. L., Park, C. H., Reed, N. R., Hesse, S. E., Thomas, C. F., Molina, J. R., Deschamps, C. C., Yang, P., Aubry, M. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn365 · Cited by 76

Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction

Benvenuti, S., Lazzari, L., Arnesano, A., Chiavi, G. L., Gentile, A., & Comoglio, P. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2100 · Cited by 79

Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation

Lin, T., & Hsu, H.-Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.018 · Cited by 75

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

Nakamura, T., Sueoka‐Aragane, N., Iwanaga, K., Sato, A., Komiya, K., Abe, T., Ureshino, N., Hayashi, S., Hosomi, T., Hirai, M., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822956e8 · Cited by 74

Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model

Kao, H.-W., Lin, Y.-Y., Chen, C., Chi, K., Tien, D., Hsia, C.-C., Lin, W., Chen, F., Lin, M.-H., & Wang, H. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/29/295102 · Cited by 74

KPT-330 has antitumour activity against non-small cell lung cancer

Sun, H., Hattori, N., Chien, W., Sun, Q., Sudo, M., E-Ling, G. L., Ding, L., Lim, S. L., Shacham, S., Kauffman, M. G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.260 · Cited by 74

Biomarkers in Lung Adenocarcinoma: A Decade of Progress

Sholl, L. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0128-ra · Cited by 75

High specific detection and near-infrared photothermal therapy of lung cancer cells with high SERS active aptamer–silver–gold shell–core nanostructures

Wu, P., Gao, Y., Lu, Y., Zhang, H., & Cai, C. (2013) · The Analyst · doi:10.1039/c3an01375h · Cited by 74

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

Azoitei, N., Hoffmann, C. M., Ellegast, J. M., Ball, C. R., Obermayer, K., Gößele, U., Koch, B., Faber, K., Genze, F., Schrader, M. G., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111910 · Cited by 74

Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes

Lozano, M. D., Zulueta, J. J., Echeveste, J. I., Gúrpide, A., Seijo, L. M., Martín‐Algarra, S., del Barrio, A., Pı́o, R., Idoate, M. A., Labiano, T., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0155 · Cited by 74

The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family

Kennedy, S. P., Hastings, J. F., Han, J. Z. R., & Croucher, D. R. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00088 · Cited by 74

Discovery of EGF Receptor Inhibitors That Are Selective for the d746‐750/T790M/C797S Mutant through Structure‐Based de Novo Design

Park, H., Jung, H., Mah, S., & Hong, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201703389 · Cited by 74

Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma

Wangari‐Talbot, J., & Hopper-Borge, E. A. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.04.5 · Cited by 80

Matrix Metalloproteinase-Responsive Mesoporous Silica Nanoparticles Cloaked with Cleavable Protein for “Self-Actuating” On-Demand Controlled Drug Delivery for Cancer Therapy

Vaghasiya, K., Ray, E., Sharma, A., Katare, O. P., & Verma, R. K. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00497 · Cited by 73

Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy

Silva, V. R., Neves, S. P., Santos, L. D. S., Dias, R. B., & Bezerra, D. P. (2020) · Cancers · doi:10.3390/cancers12113461 · Cited by 77

Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR

Chung, K.-P., Wu, S.-G., Wu, J.-Y., Yang, J. C.-H., Yu, C.-J., Wei, P.-F., Shih, J.-Y., & Yang, P.-C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2353 · Cited by 72

Emerging Trends in the Application of Green Synthesized Biocompatible ZnO Nanoparticles for Translational Paradigm in Cancer Therapy

Naser, S. S., Ghosh, B., Simnani, F. Z., Singh, D., Choudhury, A., Nandi, A., Sinha, A., Jha, E., Panda, P. K., Suar, M., et al. (2023) · Journal of Nanotheranostics · doi:10.3390/jnt4030012 · Cited by 72

Overexpression of deubiquitinating enzyme USP 28 promoted non‐small cell lung cancer growth

Zhang, L., Xu, B., Qiang, Y., Huang, H., Wang, C., Li, D., & Qian, J. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12426 · Cited by 72

Advances on EGFR mutation for lung cancer.

Metro, G., & Crinò, L. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.12.01 · Cited by 73

Tumor‐Targeting of EGFR Inhibitors by Hypoxia‐Mediated Activation

Karnthaler‐Benbakka, C., Groza, D., Kryeziu, K., Pichler, V., Roller, A., Berger, W., Heffeter, P., & Kowol, C. R. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403936 · Cited by 72

EGFR mutation status in brain metastases of non-small cell lung carcinoma

Burel‐Vandenbos, F., Ambrosetti, D., Coutts, M., & Pédeutour, F. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0990-5 · Cited by 72

Lung Injury and Cancer

Goldkorn, T., & Filosto, S. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0220rt · Cited by 72

ID1 Facilitates the Growth and Metastasis of Non-Small Cell Lung Cancer in Response to Nicotinic Acetylcholine Receptor and Epidermal Growth Factor Receptor Signaling

Pillai, S., Rizwani, W., Li, X., Rawal, B., Nair, S., Schell, M. J., Bepler, G., Haura, E. B., Coppola, D., & Chellappan, S. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01311-10 · Cited by 72

The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer

Gao, X. Y., Le, X., & Costa, D. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162103 · Cited by 72

Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Gu, X., Zhang, Q., Chu, Y.-B., Zhao, Y., Zhang, Y., Kuo, D. C., Su, B., & Wu, B. Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.029 · Cited by 73

Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation

Tan, X., Lu, T., Li, L., Xu, J., Xie, S., Ji, L., Fu, J., Liu, Q., Shen, S., Liu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24898-9 · Cited by 72

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 73

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives

Tang, J., Salama, R., Gadgeel, S. M., Sarkar, F. H., & Ahmad, A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00015 · Cited by 73

Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification

Coumar, M. S., Chu, C., Lin, C., Shiao, H., Ho, Y.-L., Reddy, R., Lin, W., Chen, C.-H., Peng, Y., Leou, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000198 · Cited by 71

Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas

de Muga, S., Hernandez, S. F., Agell, L., Salido, M., Juanpere-Rodero, N., Lorenzo, M., Lorente, J. A., Serrano, S., & Lloreta, J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.45 · Cited by 71

Opposing Functions of Akt Isoforms in Lung Tumor Initiation and Progression

Linnerth-Petrik, N. M., Santry, L. A., Petrik, J., & Wootton, S. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094595 · Cited by 74

Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies

Warth, A., Penzel, R., Brandt, R., Sers, C., Fischer, J. R., Thomas, M., Herth, F. J. F., Dietel, M., Schirmacher, P., & Bläker, H. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1219-x · Cited by 71

Hypoxia induces gefitinib resistance in non‐small‐cell lung cancer with both mutant and wild‐type epidermal growth factor receptors

Minakata, K., Takahashi, F., Nara, T., Hashimoto, M., Tajima, K., Murakami, A., Nurwidya, F., Yae, S., Koizumi, F., Moriyama, H., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02408.x · Cited by 73

How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors

Milik, S. N., Lasheen, D. S., Serya, R. A. T., & Abouzid, K. A. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.023 · Cited by 71

Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells

Kobayashi, I., Takahashi, F., Nurwidya, F., Nara, T., Hashimoto, M., Murakami, A., Yagishita, S., Tajima, K., Hidayat, M., Shimada, N., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.064 · Cited by 70

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer

Veldore, V. H., Choughule, A. B., Routhu, T., Mandloi, N., Noronha, V., Joshi, A., Dutt, A., Gupta, R. K., Ramprasad, V. L., & Prabhash, K. (2018) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s147841 · Cited by 70

Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR -Mutant Lung Cancer

Biswas, A. K., Han, S., Tai, Y., Ma, W., Coker, C., Quinn, S. A., Shakri, A. R., Zhong, T. J., Scholze, H., Lagos, G. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0910 · Cited by 70

Electrochemical detection of ctDNA mutation in non-small cell lung cancer based on CRISPR/Cas12a system

Liu, F., Peng, J., Lei, Y., Liu, R., Jin, L. J., Liang, H., Liu, H., Ma, S., Zhang, X., Zhang, Y., et al. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.131807 · Cited by 70

Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease

Sato, T., Arai, E., Kohno, T., Takahashi, Y., Miyata, S., Tsuta, K., WATANABE, S.-I. I., Soejima, K., Betsuyaku, T., & Kanai, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28684 · Cited by 70

Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non–Small Cell Lung Cancer Cells

Kharbanda, A., Rajabi, H. N., Jin, C., Tchaicha, J. H., Kikuchi, E., Wong, K., & Kufe, D. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3168 · Cited by 70

Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies

Stella, G. M., Luisetti, M., Inghilleri, S., Cemmi, F., Scabini, R., Zorzetto, M., & Pozzi, E. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.015 · Cited by 73

EGFR inhibition in the treatment of non‐small cell lung cancer

Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 70

Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts

Ma, X., Lv, X., & Zhang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.049 · Cited by 71

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Metro, G., Chiari, R., Duranti, S., Siggillino, A., Fischer, M. J., Giannarelli, D., Ludovini, V., Bennati, C., Marcomigni, L., Baldi, A., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.06.005 · Cited by 71

Effects of WSG, a polysaccharide from Ganoderma lucidum, on suppressing cell growth and mobility of lung cancer

Hsu, W.-H., Qiu, W.-L., Tsao, S.-M., Tseng, A.-J., Lu, M., Hua, W.-J., Cheng, H.-C., Hsu, H.-Y., & Lin, T. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.09.227 · Cited by 69

Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors

Zhang, B., Liu, Z., Xia, S., Liu, Q., & Gou, S.-H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113300 · Cited by 69

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

Saad, A. G., Yeap, B. Y., Thunnissen, E., Pinkus, G. S., Pinkus, J. L., Loda, M. F., Sugarbaker, D. J., Johnson, B. E., & Chirieac, L. R. (2008) · Cancer · doi:10.1002/cncr.23826 · Cited by 69

Personalized Targeted Therapy for Lung Cancer

Wu, K., House, L. K., Liu, W., & Cho, W. C. S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911471 · Cited by 71

HER3 and mutant EGFR meet MET

Arteaga, C. L. (2007) · Nature Medicine · doi:10.1038/nm0607-675 · Cited by 69

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

Tabara, K., Kanda, R., Sonoda, K., Kubo, T., Murakami, Y., Kawahara, A., Azuma, K., Abe, H., Kage, M., Yoshinaga, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041017 · Cited by 70

Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation

Wu, B.-K., & Brenner, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.063 · Cited by 69

Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC)

Pawara, R. H., Ahmad, I., Nayak, D., Wagh, S. S., Wadkar, A. R., Ansari, A., Belamkar, S., Surana, S. J., Kundu, C. N., Patil, C., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105234 · Cited by 69

Reengineered tricyclic anti-cancer agents

Kastrinsky, D. B., Sangodkar, J., Zaware, N., Izadmehr, S., Dhawan, N. S., Narla, G., & Ohlmeyer, M. H. J. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.007 · Cited by 71

Lung cancer in women

Rodríguez, R. B., & Morales-Fuentes, J. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s37319 · Cited by 71

In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor

Singh, P., & Bast, F. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1090-1 · Cited by 69

Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?

Guéguinou, M., Gambade, A., Félix, R., Chantôme, A., Fourbon, Y., Bougnoux, P., Weber, G., Potier‐Cartereau, M., & Vandier, C. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.036 · Cited by 68

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Sun, J.-M., Choi, Y.-L., Ji, J. H., Ahn, J. S., Kim, K.-M., Han, J., Ahn, M.-J., & Park, K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu504 · Cited by 68

Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

Yamazaki, S., Vicini, P., Shen, Z., Zou, H. Y., Lee, J. J., Li, Q., Christensen, J. G., Smith, B. J., & Shetty, B. V. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188870 · Cited by 69

Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer

Dermawan, J. K. T., Gurova, K. V., Pink, J. J., Dowlati, A., De, S., Narla, G., Sharma, N., & Stark, G. R. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0013 · Cited by 68

Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells

Dhar, S. S., Alam, H., Li, N., Wagner, K. W., Chung, J., Ahn, Y. W., & Lee, M. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521625 · Cited by 68

ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis

Sebille, Y. Z. A. V., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.011 · Cited by 68

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 72

Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents

Elrazaz, E. Z., Serya, R. A. T., Ismail, N. S. M., Ella, D. A. A. E., & Abouzid, K. A. M. (2015) · Future Journal of Pharmaceutical Sciences · doi:10.1016/j.fjps.2015.09.001 · Cited by 68

Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation

Bollinger, M. K., Agnew, A. S., & Mascara, G. P. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217712401 · Cited by 69

Indole-3-carbinol Inhibits 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Plus Benzo(a)pyrene–Induced Lung Tumorigenesis in A/J Mice and Modulates Carcinogen-Induced Alterations in Protein Levels

Kassie, F., Anderson, L., Scherber, R. M., Yu, N., Lahti, D., Upadhyaya, P., & Hecht, S. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4438 · Cited by 68

In-Depth Analysis Shows Synergy between Erlotinib and miR-34a

Zhao, J. Y., Kelnar, K., & Bader, A. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089105 · Cited by 67

Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant

Zhou, W., Liu, X., Tu, Z., Zhang, L., Ku, X., Bai, F., Zhao, Z., Xu, Y. F., Ding, K., & Li, H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401045n · Cited by 67

Acquisition of anoikis resistance promotes alterations in the Ras/ERK and PI3K/Akt signaling pathways and matrix remodeling in endothelial cells

Mesquita, A. P. D. S., Lopes, S. D. A., Filho, P. C. A. P., Nader, H. B., & Lopes, C. C. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1392-0 · Cited by 68

Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy

Barui, S., & Cauda, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060527 · Cited by 73

Computational identification of 2,4-disubstituted amino-pyrimidines as L858R/T790M-EGFR double mutant inhibitors using pharmacophore mapping, molecular docking, binding free energy calculation, DFT study and molecular dynamic simulation

Pawara, R. H., Ahmad, I., Surana, S. J., & Patel, H. (2021) · In Silico Pharmacology · doi:10.1007/s40203-021-00113-x · Cited by 69

PROTACs: A novel strategy for cancer drug discovery and development

Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69

Recent advances of novel targeted therapy in non-small cell lung cancer

Katzel, J. A., Fanucchi, M. P., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-2 · Cited by 70

Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo

Ichihara, E., Ohashi, K., Takigawa, N., Osawa, M., Ogino, A., Tanimoto, M., & Kiura, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4204 · Cited by 67

Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation

Jurišić, V., Obradović, J., Pavlović, S., & Djordjević, N. (2018) · Analytical Cellular Pathology · doi:10.1155/2018/6192187 · Cited by 67

Recent advances in the development of EGFR degraders: PROTACs and LYTACs

Hong, D., Zhou, B., Zhang, B., Ren, H., Zhu, L., Zheng, G., Ge, M., & Ge, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114533 · Cited by 67

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma

Suda, T., Hama, T., Kondo, S., Yuza, Y., Yoshikawa, M., Urashima, M., Kato, T., & Moriyama, H. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-416 · Cited by 66

Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

Dietel, M., Jöhrens, K., von Laffert, M., Hummel, M., Bläker, H., Müller, B. M., Lehmann, A., Denkert, C., Heppner, F. L., Koch, A., et al. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.13 · Cited by 66

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

Zhang, W., Peyton, M., Xie, Y., Soh, J., Minna, J. D., Gazdar, A. F., & Frenkel, E. P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318194fae7 · Cited by 66

Oncogenic driver mutations in lung cancer

Luo, S. Y., & Lam, D. C.-L. (2013) · Translational Respiratory Medicine · doi:10.1186/2213-0802-1-6 · Cited by 70

The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors

Schneider, M. R., & Yarden, Y. (2015) · Oncogene · doi:10.1038/onc.2015.372 · Cited by 69

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156